

Hoda M Hassab

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5180975/publications.pdf>

Version: 2024-02-01

24
papers

722
citations

1163117

8
h-index

752698

20
g-index

24
all docs

24
docs citations

24
times ranked

873
citing authors

#	ARTICLE	IF	CITATIONS
1	Beta Thalassemia Carrier rate: Problem Burden Among High School Children. <i>Current Pediatric Reviews</i> , 2022, 18, .	0.8	0
2	Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e323-e333.	4.6	61
3	SLC25A38 congenital sideroblastic anemia: Phenotypes and genotypes of 31 individuals from 24 families, including 11 novel mutations, and a review of the literature. <i>Human Mutation</i> , 2021, 42, 1367-1383.	2.5	11
4	Comparing the effect of acupressure and ginger on chemotherapy gastrointestinal side-effects in children with leukemia. <i>Complementary Therapies in Medicine</i> , 2021, 60, 102730.	2.7	8
5	Prevalence of iron deficiency anemia and beta thalassemia carriers among relatives of beta thalassemia patients in Nile Delta region, Egypt: a multicenter study. <i>Journal of the Egyptian Public Health Association</i> , 2021, 96, 27.	2.5	5
6	Low-dose immune tolerance induction therapy in children of Arab descent with severe haemophilia A, high inhibitor titres and poor prognostic factors for immune tolerance induction treatment success. <i>Haemophilia</i> , 2021, 28, 65.	2.1	3
7	Evaluation of the efficacy and safety of deferasiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. <i>Lancet Haematology</i> , 2020, 7, e469-e478.	4.6	39
8	Efficacy and Safety of Voxelotor in Adolescents and Adults with Sickle Cell Disease: HOPE Trial 72-Week Analysis. <i>Blood</i> , 2020, 136, 19-19.	1.4	3
9	A Phase 3 Randomized Trial of Voxelotor in Sickle Cell Disease. <i>New England Journal of Medicine</i> , 2019, 381, 509-519.	27.0	401
10	Geographic Differences in Phenotype and Treatment of Children with Sickle Cell Anemia from the Multinational DOVE Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 2009.	2.4	8
11	Evaluation of multiplexed biomarkers in assessment of CSF infiltration in pediatric acute lymphoblastic leukemia. <i>International Journal of Hematologic Oncology</i> , 2019, 8, IJH22.	1.6	3
12	Novel findings from the multinational DOVE study on geographic and age-related differences in pain perception and analgesic usage in children with sickle cell anaemia. <i>British Journal of Haematology</i> , 2019, 184, 1058-1061.	2.5	13
13	Intracranial Hemorrhage in Egyptian Children with Primary Immune Thrombocytopenia (ITP): Report of 24 Cases in 20 Years. <i>Blood</i> , 2019, 134, 1080-1080.	1.4	1
14	Neutropenia in Children Treated with Deferiprone or Deferasirox: A Report of the Largest Randomized Trial of Oral Chelators in Transfusion-Dependent Pediatric Patients. <i>Blood</i> , 2019, 134, 3552-3552.	1.4	2
15	Deviation from Guidelines in Use of Eltrombopag and Romiplostim in Clinical Practice for Children with Primary Immune Thrombocytopenia; Multi-Center Egyptian Experience. <i>Blood</i> , 2019, 134, 4907-4907.	1.4	0
16	Results from Part A of the Hemoglobin Oxygen Affinity Modulation to Inhibit HbS Polymerization (HOPE) Trial (GBT440-031), a Placebo-Controlled Randomized Study Evaluating Voxelotor (GBT440) in Adults and Adolescents with Sickle Cell Disease. <i>Blood</i> , 2018, 132, 505-505.	1.4	3
17	A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. <i>New England Journal of Medicine</i> , 2016, 374, 625-635.	27.0	117
18	Neurophysiologic Evaluation of Children with Beta-Thalassemia Major. <i>Journal of Pediatric Neurology</i> , 2015, 13, 110-115.	0.2	0

#	ARTICLE	IF	CITATIONS
19	Lymphadenopathy in a Series of Egyptian Pediatric Patients and the Role of Pathology in the Diagnostic Workup. <i>Pediatric and Developmental Pathology</i> , 2014, 17, 344-359.	1.0	11
20	Lymphadenopathy in a Series of Egyptian Pediatric Patients and the Role of Pathology in the Diagnostic Workup.. <i>Pediatric and Developmental Pathology</i> , 2014, , .	1.0	2
21	Intracranial Hemorrhage in Acute and Chronic Childhood Immune Thrombocytopenic Purpura over a Ten-Year Period: An Egyptian Multicenter Study. <i>Acta Haematologica</i> , 2010, 123, 59-63.	1.4	22
22	Phenotypic analysis of bone marrow lymphocytes from children with acute thrombocytopenic purpura. <i>The Egyptian Journal of Immunology / Egyptian Association of Immunologists</i> , 2005, 12, 9-14.	0.4	5
23	Granulocyte-macrophage colony-stimulating factor (GM-CSF) in children with acute immune thrombocytopenic purpura. <i>Medical Science Monitor</i> , 2004, 10, CR330-5.	1.1	3
24	Does TGFBR3 Polymorphism Increase the Risk of Silent Cerebral Infarction in Egyptian Children with Sickle Cell Disease?. <i>Indian Journal of Pediatrics</i> , 0, , .	0.8	1